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Abstract 
Autosomal dominant hypocalcemia (ADH) is characterized by hypocalcemia, inappropriately low 
serum parathyroid hormone concentrations and hypercalciuria. ADH is genetically heterogeneous 
with ADH type 1 (ADH1), the predominant form, being caused by germline gain-of-function 
mutations of the G-protein coupled calcium-sensing receptor (CaSR), and ADH2 caused by 
germline gain-of-function mutations of G-protein subunit α-11 (Gα11). To date Gα11 mutations 
causing ADH2 have been reported in only five probands. We investigated a multi-generational non-
consanguineous family, from Iran, with ADH and keratoconus which are not known to be 
associated, for causative mutations by whole-exome sequencing in two individuals with 
hypoparathyroidism, of whom one also had keratoconus, followed by cosegregation analysis of 
variants. This identified a novel heterozygous germline Val340Met Gα11 mutation in both 
individuals, and this was also present in the other 2 relatives with hypocalcemia that were tested.  
Three-dimensional modeling revealed the Val340Met mutation to likely alter the conformation of 
the C-terminal 5 helix, which may affect G-protein coupled receptor binding and G-protein 
activation. In vitro functional expression of wild-type (Val340) and mutant (Met340) Gα11 proteins 
in HEK293 cells stably expressing the CaSR, demonstrated that the intracellular calcium responses 
following stimulation with extracellular calcium, of the mutant Met340 Gα11 led to a leftward shift 
of the concentration-response curve with a significantly (p<0.0001) reduced mean half-maximal 
concentration (EC50) value of 2.44 mM (95% CI  = 2.31-2.77 mM) when compared to the wild-type 
EC50 of 3.14 mM (95% CI = 3.03-3.26 mM), consistent with a gain-of-function mutation. A novel 
His403Gln variant in transforming growth factor, beta-induced (TGFBI), that may be causing 
keratoconus was also identified, indicating likely digenic inheritance of keratoconus and ADH2 in 
this family. In conclusion, our identification of a novel germline gain-of-function Gα11 mutation, 
Val340Met, causing ADH2 demonstrates the importance of the G11 C-terminal region for G-
protein function and CaSR signal transduction. This article is protected by copyright. All rights 
reserved 
Keywords: whole-exome sequencing; G-protein; calcium; hypoparathyroidism; keratoconus 
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Introduction 
Autosomal dominant hypocalcemia (ADH) is a disorder of systemic calcium homeostasis that is 
associated with enhanced sensitivity of the calcium-sensing receptor (CaSR) to extracellular 
calcium (Ca
2+
o) concentrations.
(1-3)
 The CaSR is a guanine-nucleotide binding protein (G-protein)-
coupled receptor (GPCR) that plays a pivotal role in Ca
2+
o homeostasis by transducing increases in 
the prevailing Ca
2+
o concentration into multiple signaling cascades that include Gq/11-protein 
mediated activation of phospholipase C (PLC), which in the parathyroid glands and kidneys induces 
rapid increases in intracellular calcium (Ca
2+
i) that lead to decreased parathyroid hormone (PTH) 
secretion and increased urinary calcium excretion, respectively.
(2,4,5)
 ADH is a genetically 
heterogeneous disorder most commonly caused by germline gain-of-function mutations of the 
CaSR, which is encoded by the CASR gene on chromosome 3q21.1, and this is referred to as ADH 
type 1 (ADH1; OMIM #601198).
(1,2,5)
 However, some ADH patients and families have recently 
been shown to harbor germline mutations of G-protein subunit-α11 (Gα11), which is encoded by the 
GNA11 gene (Fig. 1) on chromosome 19p13.3,
(3,6,7)
 and referred to as ADH type 2 (ADH2; OMIM 
#615361).
(3)
 These ADH-associated Gα11 mutations have been demonstrated to enhance CaSR-
mediated signaling in cellular studies, consistent with a gain-of-function.
(3,7)
 ADH1 patients have 
calcitropic phenotypes, such as hypocalcemia with inappropriately low or normal PTH 
concentrations and a relative hypercalciuria that is characterised by urinary calcium to creatinine 
ratios that are within or above the reference range,
(1,8,9)
 and mice with a gain-of-function CaSR 
mutation, that are representative of ADH1, have been reported to also have non-calcitropic 
phenotypes such as cataracts.
(10)
 Although these features are similar to hypoparathyroidism, ADH1 
is considered to represent a distinct disease entity from hypoparathyroidism, as affected individuals 
generally have PTH concentrations that are detectable and within the reference range,
(1,8)
. 
Furthermore, ADH1 patients may also develop a Bartter-like syndrome characterised by 
hypokalemic alkalosis, renal salt wasting and hyperreninemic hyperaldosteronism,
(11,12)
 and the use 
of active vitamin D metabolites to treat symptomatic ADH1 patients may result in the development 
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of marked hypercalciuria, nephrocalcinosis, nephrolithiasis and renal impairment.
(1,9)
 In contrast to 
ADH1, the phenotypic spectrum of ADH2 has not been fully elucidated, especially as only 5 ADH2 
probands with Gα11 mutations (Fig. 1) have been reported to date.
(3,6,7)
 Thus, it remains to be 
established whether ADH2 patients with germline gain-of-function Gα11 mutations are susceptible 
to hypercalciuria, particularly when treated with active vitamin D preparations, or at risk of a 
Bartter-like syndrome. Moreover, Gα11 is a widely expressed protein that mediates the biological 
effects of GPCRs in a range of tissues,
(13)
 and it is currently unknown whether patients with ADH2 
may harbor additional calcitropic and non-calcitropic phenotypes. We ascertained a family with 
ADH and keratoconus, a non-calcitropic disorder of the cornea, and hypothesized that either a 
single genetic abnormality may be causing ADH and keratoconus, or that ADH and keratoconus 
may be due to two different genetic abnormalities, i.e. digenic inheritance.  To explore these 
hypotheses, we undertook whole-exome sequencing (WES) analysis of two relatives, both of whom 
had hypocalcemia, and one of whom also had keratoconus, to identify the causative variant(s).  
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Materials and Methods 
Patients 
The proband (individual I.4, Fig. 2A) is a 66-year-old male, from Iran, who was diagnosed with 
hypocalcemia at the age of 16 years following a childhood history of intermittent muscle cramps. 
His serum adjusted-calcium concentrations have ranged from 1.82-1.95mmol/L (normal range = 
2.20-2.60 mmol/L), in association with mild hyperphosphatemia (serum phosphate = 1.42-1.81 
mmol/L; normal range = 0.80-1.45 mmol/L), normal serum creatinine concentrations of 72-80 
μmol/L (normal range = 44-133 μmol/L), low/normal serum PTH concentrations of 4.0-18.7 pg/mL 
(normal range = 12-65 pg/mL), a normal 25-hydroxyvitamin D concentration of 18.7 ng/ml (normal 
range = 10-50 ng/ml) and a normal 1,25-dihydroxyvitamin D concentration of 25.7 pg/ml (normal 
range = 16-45 pg/ml). He had been treated with oral calcium and active vitamin D preparations, and 
developed non-obstructive bilateral nephrolithiasis in association with urinary calcium values 
ranging from 4.3-10.2 mmol/24-hours (normal range = 2.5-7.5 mmol/24-hours). He was found to 
have mild bilateral cataracts at the age of 62 years. His family history revealed that 11 relatives (7 
males and 4 females) over 3 generations had hypocalcemia, with symptoms such as seizures, 
muscle cramps, and tetany. Affected relatives also had low circulating PTH concentrations, and 
relative or absolute hypercalciuria (Fig. 2A), and these findings supported a diagnosis of ADH. Five 
hypocalcemic family members (3 males and 2 females) and one normocalcemic family member 
also had keratoconus, a corneal disorder, which in individuals II.3, II.5 and II.7 (Fig. 2A) had 
developed between the ages of 30 and 34 years.
(14)
 There was no consanguinity and the inheritance 
of hypocalcemia from father to son in individuals, e.g:  from I.1 to II.1 and II.2; I.4 to II.5; and II.5 
to III.1 (Fig. 2A), indicated that hypocalcemia was transmitted as an autosomal dominant disorder. 
Similarily, the inheritance of keratoconus from father to son in individuals II.5 to III.1 (Fig. 2A), 
may be because keratoconus is transmitted as an autosomal dominant disorder, but the occurrence 
of keratoconus in the children (II.3, II.5 and II.7; and II.8) of unaffected parents (I.4 and I.5; and I.8 
and I.9, respectively, Fig 2A) indicates an autosomal recessive inheritance or autosomal dominant 
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inheritance with reduced penetrance.  To investigate the cause of the hypocalcemia and keratoconus 
in this family, venous blood samples were collected from four available patients, of whom two had 
hypocalcemia only (individuals I.4 and II.4), and two others had both hypocalcemia and 
keratoconus (individuals II.3 and II.5, Fig. 2A). Leucocyte DNA was extracted using the Gentra 
PureGene blood kit (Qiagen). CaSR mutations, which would cause ADH1, and mutations of 3 
genes, GCMB, PTH, and AIRE1, which are known to cause hypoparathyroidism had been 
previously excluded by an accredited genetics diagnostic laboratory. Informed consent was 
obtained from all participants included in the study, using protocols approved by the UK 
Multicentre Research Ethics Committee (MREC/02/2/93) and the Hospital Research Ethics in 
Israel.  
 
Exome capture and DNA sequence analysis 
Exome capture was performed in individual I.4, who was affected with hypocalcemia, and in 
individual II.5, who was affected with both hypocalcemia and keratoconus (Fig. 2A), using the 
SeqCap EZ Human Exome Library v2.0 (Roche NimbleGen),
(15)
 and DNA sequences determined 
using a 100 bp paired-end read protocol on an Illumina HiSeq2000 platform.
(15)
 A minimum of 20x 
vertical read depth was obtained for >88% of the coding exome, as specified by the consensus 
coding sequence (CCDS) project,
(16)
 in both individuals.  Reads were aligned to the Human 
Sequence version 37d5 (hs37d5) reference genome using Stampy 
(17)
 and variant calling of single 
nucleotide variants (SNVs) and short insertions and deletions (indels) was undertaken using 
Platypus (v0.5.1).
(18)
 Analysis of coding variants was undertaken using Ingenuity Variant Analysis. 
To search for variants causing hypocalcemia and keratoconus under autosomal dominant 
inheritance models, variants with a minor allele frequency (MAF) >5% within all populations of 
100 genomes data (April 2012 phase 1 call set (v3 update)) and from the National Heart, Lung, and 
Blood Institute (NHLBI) exome sequencing project (Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA (evs.gs.washington.edu/EVS), were excluded.  To search 
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for variants causing keratoconus under an autosomal recessive inheritance model, variants with a 
MAF >5% were not excluded. The pathogenicity of variants was inferred from several criteria: 
allele frequency within the NHLBI exome sequencing project and the Exome Aggregation 
Consortium (ExAC), Cambridge, MA (http://exac.broadinstitute.org), amino acid conservation, 
physicochemical alterations in amino acid substitutions, splice site prediction algorithms 
(NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html), MaxEntScan 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html), GeneSplicer 
(http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml) and SpliceSiteFinder-Like 
(http://www.genet.sickkids.on.ca/~ali/splicesitefinder.html)), and literature review. Variants of 
interest were confirmed by polymerase chain reaction (PCR) and Sanger DNA sequence analysis of 
the appropriate exons, using leucocyte DNA samples from the 4 available family members and 2 
unrelated unaffected individuals, as reported.
(19)
 
 
Protein sequence alignments and three-dimensional modeling 
Amino acid sequences of G-subunit paralogs and TGFBI orthologs were aligned using the Clustal 
Omega program (European Bioinformatics Institute, the European Molecular Biology Laboratory). 
The crystal structure of Gq in complex with the GTP analogue GDP-AIF4 has been determined 
(Protein Data Bank (PDB) accession number 3OHM),
(20)
 and this was used to model G11, which 
has 90% identity with Gq at the amino acid level, using the PyMOL Molecular Graphics System 
(Version 1.2r3pre, Schrodinger, LLC). 
 
Cell Culture and Transfection 
The generation of wild-type and mutant Leu341 pBI-CMV2-GNA11 expression constructs have 
been reported.
(3)
 Site-directed mutagenesis was used to generate the Val to Met mutation at codon 
340 in the pBI-CMV2-GNA11 construct using the Quikchange Lightning Site-directed Mutagenesis 
kit (Agilent Technologies) and gene-specific primers (SigmaAldrich), as reported.
(19)
 For all 
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studies, empty vector, wild-type or mutant pBI-CMV2-GNA11 expression constructs were 
transiently transfected into human embryonic kidney (HEK) 293 cells stably expressing the CaSR 
(HEK293-CaSR) using Lipofectamine 2000 (LifeTechnologies).
(21)
 Cells were maintained in 
DMEM-Glutamax media (ThermoFisher) with 10% fetal bovine serum (Gibco) and 400µg/mL 
geneticin (ThermoFisher) at 37ºC, 5% CO2.  Successful transfection was confirmed by visualising 
GFP fluorescence using an Eclipse E400 fluorescence microscope with a Y-FL Epifluorescence 
attachment and a triband 4,6-diamidino-2-phenylindole-FITC-Rhodamine filter, and images 
captured using a DXM1200C digital camera and NIS Elements software (Nikon).
(3,21,22)
 The 
expression of Gα11 and CaSR proteins was also determined by Western blot analysis using anti-
Gα11 (SantaCruz), anti-GFP (SantaCruz), anti-calnexin (Millipore) or anti-CaSR (Abcam) 
antibodies. The Western blots were visualized using Immuno-Star WesternC kit (BioRad) on a 
BioRad Chemidoc XRS+ system.
(3)
  
 
Intracellular Calcium Measurements 
The Ca
2+
i responses of HEK293-CaSR cells expressing wild-type or mutant Gα11 proteins were 
assessed by a flow cytometry-based assay, as reported.
(2,3,21,22)
 In brief, HEK293-CaSR cells were 
plated in T75 flasks and transiently transfected 24 hours later with 16µg DNA.
(3)
 At 48-hours post-
transfection, cells were detached, resuspended in calcium (Ca
2+
) and magnesium (Mg
2+
) free 
Hanks’ buffered saline solution (HBSS) and loaded with 1µg/mL Indo-1-acetoxymethylester (Indo-
1-AM) for 1 hour at 37ºC. After removal of free dye, the cells were resuspended in Ca
2+
 and Mg
2+
-
free HBSS and maintained at 37°C. Transfected cells, in suspension, were analysed by flow 
cytometry on a MoFlo modular flow cytometer (Beckman Coulter) and data on the Ca
2+
i responses 
to alterations in Ca
2+
o collected from all cells that expressed GFP, by simultaneous measurements of 
GFP expression (at 525nm), Ca
2+
i-bound Indo-1AM (at 410nm), and free Indo-1AM (i.e. not bound 
to Ca
2+
i) (at 485nm), using a JDSU Xcyte laser (Coherent Radiation), on each cell at each Ca
2+
o 
concentration [Ca
2+
]o, as described.
(3,21)
 Assays were performed in four biological replicates for 
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each of the expression constructs. The peak mean fluorescence ratio of the transient response after 
each individual stimulus was measured using Cytomation Summit software (Beckman Coulter), and 
expressed as a normalised response, as previously described.
(3,21)
 Nonlinear regression of 
concentration-response curves was performed with GraphPad Prism using the normalised response 
at each [Ca
2+
]o for each separate experiment for the determination of the EC50 (i.e., [Ca
2+
]o required 
for 50% of the maximal response). Data is presented as mean with confidence interval or mean ± 
standard error of the mean (SEM). Statistical analysis was performed using the F-test. A value of 
p<0.05 was considered significant for all analyses.  
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Results 
Identification of a novel Val340Met G11 mutation  
Exome capture and high-throughput sequence analysis of genomic DNA from two affected 
individuals, one with hypocalcemia (individual I.4) and the other with hypocalcemia and 
keratoconus (individual II.5) (Fig. 2A) resulted in the detection of >5,000 non-dbSNP variants in 
both individuals. The exclusion of variants with a MAF of >5% resulted in the identification of 104 
novel variants in 103 genes, of which three variants were excluded as sequence artefacts as they 
occurred within trinucleotide repeats. The only variant identified in a gene previously associated 
with hypocalcemia, was a heterozygous G>A transition at nucleotide c.1018 (c.1018G>A), located 
in exon 7 of the GNA11 gene (Fig. 1). The variant was confirmed by Sanger DNA sequencing to be 
present in both patients affected with hypocalcemia (individuals I.4 and II.5) and in two other 
family members (individuals II.3 and II.4) with hypocalcemia from whom samples were available 
(Fig. 2B). This G>A transition (GTG to ATG) resulted in a missense substitution, Val340Met, of 
the encoded Gα11 protein (Fig. 2C). The absence of this DNA sequence abnormality in >60,000 
exomes from the Exome Aggregation Consortium (ExAC), together with evolutionary conservation 
of the Val340 residue in vertebrate Gα-subunit paralogs (Fig. 3A) indicated that the Val340Met 
abnormality likely represented a pathogenic GNA11 mutation rather than a benign polymorphic 
variant.  
 
Identification of candidate variant for keratoconus 
Whole-exome sequencing revealed a novel heterozygous c.1209T>G transversion in TGFBI, 
encoding a variant His403Gln in transforming growth factor beta-induced (TGFBI), which was 
present in both individuals (I.4 and II.5, Fig. S1A). The TGFBI His403Gln variant is not present in 
ExAC, although a different variant in the same amino acid, His403Tyr, is present in only 3 out of 
>60,000 individuals. The His403 residue is also evolutionarily conserved in TGFBI orthologs (Fig. 
S1B).  The TGFBI variant was confirmed by Sanger DNA sequence analysis in the siblings, II.3 and 
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II.5, who had hypocalcemia and keratoconus, but its absence in the sister II.4, who has 
hypocalcemia only, indicates that this TGFBI variant is not involved in the etiology of 
hypocalcemia (Fig. S1A).  Moreover, the presence of this TGFBI variant in the father (individual 
I.4), who was affected with hypocalcemia only, indicates likely non-penetrance of the mutant allele 
(Fig. S1A).  
 
Structural characterisation of the Val340Met Gα11 mutant protein 
To evaluate whether the Val340Met GNA11 variant represents a pathogenic mutation and the cause 
of hypocalcemia in this family, structural and functional studies were undertaken. The crystal 
structure of Gq, which shares 90% amino acid identity with G11,
(3,20)
 was used to predict the 
effects of the Val340Met mutation. The mutated Val340 residue is located within the 5 helix of 
the GTPase domain of G11 (Fig. 3B-C), and next to the Phe341 residue, which has been reported 
to be associated with a gain-of-function Phe341Leu mutation (Fig. 1 and 3B) causing ADH2.
(3)
 The 
5 helix is located at the C-terminus of G-subunits and plays a critical role in GPCR binding and 
G-protein activation.
(23,24)
 Indeed, the C-terminal portion of the 5 helix, which is known as the 
interface module, directly binds to the transmembrane domain and intracellular loops of activated 
GPCRs,
(24)
 whilst the N-terminal portion, which is known as the transmission module, interacts 
with the GTPase domain β-sheet, comprising the β1-β6 strands (Fig. 3C), to mediate 
conformational changes in G-subunit structure that facilitate guanine nucleotide exchange.(23,25) 
The Val340 residue is predicted to form non-polar interactions with the conserved Phe272 and 
His327 residues, located in the β5 and β6 strands, respectively (Fig. 3C), which are considered to 
stabilize the binding of G-protein with ligand-bound GPCR.
(23,25,26)
 The Val340Met mutation is 
predicted to impair the interaction with the His327 G11 residue (Fig. 3D), thereby altering the 
conformation of the 5 helix and/or β6 strand, and destabilizing the G-GPCR complex.  
 
Functional characterisation of the Val340Met Gα11 mutant protein  
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To determine the effects of these predicted changes in Gα11 structure (Fig. 3) on CaSR-mediated 
signaling, bidirectional pBI-CMV2-GNA11 expression constructs containing wild-type (WT) 
Val340, mutant Met340, or the previously reported gain-of-function Leu341 mutant GNA11 
cDNA,
(3)
 or vector containing the green fluorescence protein (GFP) reporter gene alone were 
transiently transfected into HEK293 cells stably expressing the CaSR.  Expression of CaSR, Gα11 
and GFP was confirmed by fluorescence microscopy and/or Western blot analysis (Fig. 4A-B). 
Calnexin was used as a loading control in Western blot analyses, and Gα11 expression was 
demonstrated to be similar in cells transiently transfected with wild-type or mutant Gα11 proteins, 
and greater than that of cells transfected with the empty pBI-CMV2 vector (Fig. 4B). The responses 
of [Ca
2+
]i to alterations in [Ca
2+
]o in cells expressing the different GNA11 vectors were assessed by 
flow cytometry. The Ca
2+
i responses in wild-type and mutant Gα11-expressing cells were shown to 
increase in a dose-dependent manner following stimulation with increasing concentrations of Ca
2+
o 
between 0-15 mM. However, expression of the Met340 and Leu341 mutant Gα11 proteins resulted 
in a leftward shift of the concentration-response curves (Fig. 4C), with significantly lower half 
maximal (EC50) values, compared to wild-type Val340 G11 and empty vector (Met340 = 2.44 mM 
(95% confidence interval (CI) = 2.31-2.77 mM); Val340 = 3.14 mM (95% CI = 3.03-3.26 mM); 
empty vector = 3.12mM (95% CI = 2.99-3.25 mM); p<0.0001) (Fig. 4D).  There was no significant 
difference in the EC50 values between Met340 and Leu341 (Leu341 = 2.60mM (95% CI = 2.49-
2.72 mM); p>0.05).  Thus, the Val340Met missense substitution represents a novel gain-of-function 
G11 mutation, similar to those reported in ADH2 patients.
(3,7)
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Discussion 
The identification of a germline gain-of-function G11 mutation, Val340Met, indicates ADH2 to be 
the likely cause of hypocalcemia in this family. To date, five other hypocalcemic patients and 
families have been reported to harbor germline G11 mutations, consistent with a diagnosis of 
ADH2.
(3,6,7)
 Similar to the family characterized in this study, individuals with germline gain-of-
function G11 mutations have been reported to generally have mild-to-moderate hypocalcemia 
(serum adjusted-calcium concentrations ranging from 1.75-2.15 mmol/L) in association with serum 
PTH concentrations that are detectable and within the lower half of the normal range.
(3,6,7)
 However, 
despite ADH2 being associated with mild biochemical features, affected individuals are commonly 
symptomatic and may present with paraesthesia, muscle cramps, carpo-pedal spasms or 
seizures.
(3,6,7)
 Moreover, as described for the proband in this study (individual I.4, Fig. 2A), some 
ADH2 patients appear susceptible to treatment-related hypercalciuria, nephrocalcinosis and 
nephrolithiasis,
(7)
 although affected individuals likely have a milder urinary phenotype, with 
significantly reduced urinary calcium excretion compared to ADH1 patients who harbor gain-of-
function CaSR mutations.
(7)
 Furthermore, patients with germline heterozygous gain-of-function 
G11 mutations, in contrast to patients with germline heterozygous gain-of-function CaSR 
mutations, may have non-calcitropic phenotypes. For example, short stature caused by postnatal 
growth insufficiency was reported in affected individuals from a multi-generational kindred with 
hypocalcemia and a germline heterozygous gain-of-function mutation, Arg60Leu,
(7)
 and it is 
possible that the occurrence of mild bilateral cataracts in the proband (individual I.4) may also be 
due to the germline gain-of-function G11 mutation, Val340Met. It is also of interest to note that 
somatic G11 mutations that lead to constitutive G-protein activation are associated with the 
development of uveal melanomas.
(27)
 However, keratoconus, a corneal disorder, was not observed 
in all patients harboring the germline Val340Met G11 mutation, thereby indicating that 
keratoconus is not due to the G11 mutation. Instead, keratoconus in this family is likely due to the 
identified novel germline variant, His403Gln in TGFBI (Fig. S1), abnormalities of which have 
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previously been reported in association with keratoconus and autosomal dominant forms of corneal 
dystrophy.
(28,29)
 Thus, the occurrence of keratoconus and ADH2 in this family are not genetically 
associated, but are instead due to digenic inheritance of mutations involving TGFBI and G11.  
 
Structural and functional studies of ADH2-causing gain-of-function G11 mutations have revealed 
residues and peptide motifs critical for G-subunit function. Thus, the importance of the interface at 
which the G-subunit helical and GTPase domains interact to mediate guanine nucleotide 
exchange, has been demonstrated by the reported Arg60Leu, Arg60Cys and Arg181Gln G11 
mutations,
(3,6,7)
 which are located at the interdomain interface (Fig. 3B),
(25)
 and predicted to disrupt 
GDP binding.
(3,6,7)
 Whereas, the reported ADH2-causing Ser211Trp mutation, located in the α2 
helix of the GTPase domain (Fig. 3B), may cause a gain-of-function by dissociating the G-subunit 
from the Gγ heterodimer.(6) Furthermore, the reported ADH2-causing Phe341Leu mutation(3) is 
located in the C-terminal 5 helix, which facilitates G-protein-GPCR coupling (23), and the mutated 
Phe341 residue is predicted to play major roles in G-protein activation and inactivation.
(25,26)
 
Indeed, under basal conditions, Phe341 forms part of a hydrophobic cluster of phenylalanine 
residues that maintains the G-subunit in an inactive GDP-bound conformation.(25,26) Upon ligand-
binding, Phe341 binds to the second intracellular loop of the activated cognate GPCR,
(24)
 which 
disrupts the hydrophobic cluster, leading to the release of GDP.
(25,26)
 The Phe341Leu mutation is 
predicted to affect the hydrophobic cluster,
(3)
 thereby leading to GDP/GTP exchange and G-protein 
activation. In contrast to these roles of Phe341, the neighboring Val340 residue does not bind to 
activated GPCRs and is not involved in GDP/GTP exchange,
(24,25)
 but instead may play a role in 
stabilizing the nucleotide-free conformation of the G-subunit once bound to activated GPCR.(23) 
Thus, the Val340Met mutation likely mediates G11 activation by influencing the stability of G-
GPCR interactions. These different ADH2 mutations have yielded insights into G-subunit 
structure-function relationships, which may aid the design of novel targeted therapeutic agents for 
the treatment of ADH, for which there is currently a lack of adequate drugs.
(30)
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In conclusion, we have identified a novel germline gain-of-function G11 mutation, Val340Met, 
that causes ADH2 in a family in which some members also suffered from keratoconus.  
Keratoconus in this family was likely due to a novel germline TGFBI His403Gln variant, thereby 
indicating that keratoconus and ADH2 are not caused by the same mutation, but instead the 
combined occurrence of ADH2 and keratoconus in some family members is due to digenic 
inheritance. Finally our study provides an exemplar of the clinical utility of WES, that enabled the 
identification of two likely genetic causes by a single experimental protocol, which would not have 
been readily possible using former genetic techniques. 
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Figure legends 
Fig. 1. Schematic representation of the genomic organisation of the human GNA11 gene showing 
the location of ADH2-causing mutations. The GNA11 gene consists of 7 exons with the start (ATG) 
and stop (TGA) codons located in exons 1 and 7, respectively. The GTPase domain (encoded by 
exon 1, 5’ portion of exon 2, 3’ portion of exon 4 and exons 5-7) is connected to the helical domain 
(encoded by the 3’ portion of exon 2, exon 3, and 5’ portion of exon 4) by the linker 1 (L1) and 
linker 2 (L2) peptides. The previously reported ADH2-causing Arg60Cys (R60C), Arg60Leu 
(R60L) and Arg181Gln (R181Q) mutations
(3,6,7)
 are located at the interface between the helical and 
GTPase domains and adjacent to the linker peptides. The reported ADH2-causing Ser211Trp 
(S211W) mutation is located in the α2 helix of the GTPase domain,(6) and the Val340Met (V340M) 
mutation reported by this study (shown in bold), and the previously reported Phe341Leu (F341L) 
mutation
(3)
 are located in the α5 helix of the GTPase domain. Coding-regions are shaded gray and 
untranslated regions are represented by open boxes. 
 
Fig. 2. Identification of a Val340Met G11 mutation in a family with hypocalcemia and 
keratoconus. (A), Pedigree of the family, with males and females indicated by squares and circles, 
respectively. Individuals affected with hypocalcemia, keratoconus or the combined occurrence of 
hypocalcemia and keratoconus are indicated by left half-filled, right half-filled or filled symbols, 
respectively, and unaffected individuals are indicated by open symbols. The proband (individual 
I.4) is indicated by an arrow, and asterisks indicate those individuals from whom DNA was 
available for these studies. Plasma calcium (Ca) (mmol/L; normal range = 2.20-2.60 mmol/L) and 
plasma PTH (pg/ml; normal range = 12-65 pg/ml) values are shown for individuals I.4, II.3, II.4 
and II.5. (B), A heterozygous G>A transition at nucleotide c.1018 within exon 7 of GNA11 (Fig. 1) 
was identified by WES and confirmed by Sanger DNA sequence analysis. The c.1018G>A GNA11 
variant was detected in all 4 family members with hypocalcemia from whom samples were 
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available. (C), This DNA sequence abnormality was predicted to lead to a missense amino acid 
substitution of Val to Met at codon 340. 
 
Fig. 3. Predicted effects of the Val340Met mutation on the Gα11 protein. (A), Multiple protein 
sequence alignment of residues comprising the α5 helix of Gα-subunit paralogs. The wild-type 
Val340 (V) and mutant Met340 (M) residues are shown in bold. Conserved residues are shaded 
gray. (B), Overall three-dimensional structure of the Gα11 protein. The Gα-subunit helical (blue) and 
GTPase (green) domains are connected by the L1 and L2 peptides (gray). The five Gα11 residues, 
which have been reported to be mutated in ADH2,
(3,6,7)
 are shown in magenta. The mutated Arg60 
and Arg181 residues are located at the interdomain interface (red dashed line), which forms a 
pocket for the binding of guanine nucleotides (yellow). The GTPase domain is the location of the 
mutated Ser211 residue (α2 helix), and mutated Val340 and Phe341 residues (α5 helix). (C), Close-
up view of the α5 helix, which comprises a C-terminal interface module (pink) that interacts with 
partner GPCRs and an N-terminal transmission module (purple), which interacts with the 
surrounding β1-β6 strands to facilitate conformational changes that lead to guanine nucleotide 
exchange and Gα-subunit activation.(23) The wild-type Val340 residue (red) is predicted to form 
non-polar interactions with the Phe272 and His327 residues (cyan),
(26)
 which are located in the β5 
and β6 strands, respectively. (D), The introduction of a mutant Met340 residue (red, space filling 
model) is predicted to sterically hinder His327 (cyan, stick model), thereby altering the 
conformation of the 5 helix and/or 6 strand. 
 
Fig. 4. Functional characterisation of wild-type and ADH2-associated mutant Gα11 proteins. (A), 
Fluorescence microscopy of HEK293 cells stably expressing CaSR (HEK293-CaSR) and 
transiently transfected with wild-type (WT) or ADH2-associated mutant (Met340 and Leu341) 
GNA11-pBI-CMV2-GFP constructs, or with vector (V) only. Detection of GFP in these cells 
indicates successful transfection and expression of these constructs. Bar indicates 10μm. (B), 
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Western blot analysis of whole cell lysates using antibodies to CaSR, calnexin, Gα11 and GFP. 
Transient transfection of WT or ADH2-associated mutant constructs resulted in over-expression of 
Gα11 when normalized to calnexin expression. (C), Concentration-response curves showing 
normalized Ca
2+
i response to changes in [Ca
2+
]o of HEK293-CaSR cells transfected with WT or 
ADH2-associated Gα11 mutants. The Ca
2+
i responses are shown as the mean ± SEM of 4 
independent transfections. The ADH2-associated Gα11 mutants (Met340 and Leu341) led to a 
leftward shift of the concentration-response curves (blue and red, respectively) when compared with 
WT Gα11 (black), which harbors Val and Phe residues at codons 340 and 341, respectively. (D), 
The Met340 and Leu341 mutants (blue and red bars, respectively) were associated with 
significantly decreased EC50 values compared to cells expressing WT Gα11 (black bar). 
***p<0.0001. 
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